Gallant Reports Positive Pilot Data for Feline Therapy

Gallant, a biotechnology company specializing in stem cell therapies for pets, has announced positive results from a pilot study for its feline osteoarthritis treatment. The company is pioneering off-the-shelf stem cell therapies, aiming to provide accessible and effective solutions for common pet ailments. These promising results pave the way for expanded clinical trials and potential regulatory approval, marking a significant step forward in veterinary medicine. Gallant's innovative approach could revolutionize how osteoarthritis is managed in cats.